Exclusive Agreement Reached Between Lynk Pharmaceuticals and Formation Bio for Development of LNK01006
December 10, 2025In a significant development within the pharmaceutical industry, Lynk Pharmaceuticals Co., Ltd. (referred to as ‘Lynk Pharmaceuticals’) and Formation Bio have finalized an exclusive agreement involving the rights to LNK01006, a cutting-edge central nervous system (CNS)-penetrant highly selective TYK2 inhibitor.…
The post Exclusive Agreement Reached Between Lynk Pharmaceuticals and Formation Bio for Development of LNK01006 appeared first on ChinaPulse.com.
Original URL: Click here to visit original article